Inhibrx Inc banner

Inhibrx Inc
NASDAQ:INBX

Watchlist Manager
Inhibrx Inc Logo
Inhibrx Inc
NASDAQ:INBX
Watchlist
Price: 82.385 USD -6.62%
Market Cap: $1.2B

During the last 3 months Inhibrx Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 10% over this period (open performance analysis).

The last transaction was made on Oct 7, 2025 by Viking Global Investors Lp , who sold 10m USD worth of INBX shares.

Last Transactions:
Viking Global Investors Lp
$-10m
Kayyem Jon Faiz
$+266.1k
Kayyem Jon Faiz
$+495.7k
Vuori Kristiina Md
$+100k
Lappe Mark
$+223.3k
Lappe Mark
$+405.8k
Manhard Kimberly
$+139.8k
Forsyth Douglas
$+841.6k
Forsyth Douglas
$+195.8k
Lappe Mark
$+167.4k
Lappe Mark
$+350.9k
Eckelman Brendan P.
$-10.3m
Viking Global Investors Lp
$+9.9m
Eckelman Brendan P.
$-958.3k
Lappe Mark
$-1.5k
Eckelman Brendan P.
$-257.1k
Eckelman Brendan P.
$-326.7k
Lappe Mark
$-109.8k
Kayyem Jon Faiz
$-240k
Lappe Mark
$-549.4k
Eckelman Brendan P.
$-94.8k
Eckelman Brendan P.
$-520.1k
Kayyem Jon Faiz
$-202.6k
Lappe Mark
$-644.6k
Eckelman Brendan P.
$-561.6k
Kayyem Jon Faiz
$-80.2k
Lappe Mark
$-176.5k
Eckelman Brendan P.
$-921.7k
Kayyem Jon Faiz
$-105k
Lappe Mark
$-257.4k
Viking Global Investors Lp
$+30m
Eckelman Brendan P.
$-35.7k
View All Transactions

During the last 3 months Inhibrx Inc insiders have not bought any shares, and have not sold any shares. The stock price has increased by 10% over this period (open performance analysis).

The last transaction was made on Oct 7, 2025 by Viking Global Investors Lp , who sold 10m USD worth of INBX shares.

Sold
0-3
months
0 USD
0
3-6
months
0 USD
0
6-9
months
10m USD
1
9-12
months
0 USD
0
Bought
0-3
months
No Insider Transactions
0
0 USD
3-6
months
No Insider Transactions
0
0 USD
6-9
months
0
0 USD
9-12
months
No Insider Transactions
0
0 USD

Inhibrx Inc
Insider Trading Chart

Inhibrx Inc
Insiders Performance

1 Week Later 1 Month Later 3 Months Later 6 Months Later 1 Year Later
Average Return
Median Return
Win Rate

Inhibrx Inc
Last Insider Transactions

Global
Insiders Monitor

Inhibrx Inc
Glance View

Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The company is headquartered in La Jolla, California and currently employs 106 full-time employees. The company went IPO on 2020-08-19. The Company’s single domain antibody (sdAb) platform provides a small, simple, modular target binding domain that can be combined in to meet the needs of each biological target. Its products pipeline includes: INBRX-101 is a recombinant alpha-1 antitrypsin (AAT) protein that is comprised of two human AAT, molecules covalently linked to the fragment crystallizable (Fc) region of human immunoglobulin G4; INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate targeting death-receptor 5 (DR5) that designed with its sdAb platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis, and INBRX-105 is a precisely engineered multi-specific sdAb-based therapeutic candidate that is designed to agonize 4-1BB selectively in the presence of PD-L1.

INBX Intrinsic Value
42.899 USD
Overvaluation 48%
Intrinsic Value
Price $82.385

What is Insider Trading?

Insider trading refers to the buying or selling of a company’s stock by individuals with access to non-public, material information about the company.

While legal insider trading occurs when insiders follow disclosure rules, illegal insider trading involves trading based on confidential information and is prohibited by law.

Why is Insider Trading Important?

It isn't a coincidence that corporate executives seem to always buy at the right times. After all, they have access to every bit of company information you could ever want.

However, the fact that company executives have unique insights doesn't mean that individual investors are always left in the dark. Insider trading data is out there for all who want to use it.

Peter Lynch

Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett